Abbott Raises 2026 Outlook After Solid Q2 Beat Driven by Diagnostics and Devices
Abbott delivered robust Q2 2026 earnings driven by 42% growth in its Diagnostics segment, led by strong Cologuard adoption.
/ 220 items
#andre↓
UnitedHealth Shares Surge as Q2 Results Top Forecasts and Guidance Raised
Strong cost control and Optum performance drive recovery.
Eli Lilly Enters Psychedelic Mental Health Space with $3.8 Billion AtaiBeckley Acquisition
Eli Lilly secures BPL-003 and other novel psychedelic-inspired treatments designed to provide rapid, long-lasting relief for treatment-resistant depression.
Eli Lilly in Advanced Talks to Acquire AtaiBeckley for Psychedelic Mental Health Portfolio
The deal would boost Lilly’s psychedelic pipeline for treatment-resistant depression.
Apple Intelligence Finally Gets Green Light in China, Boosting Upgrade Hopes
Powered by Alibaba’s Qwen model, the AI features — including upgraded Siri — are set to launch this fall with iOS 27 for Chinese users.
Novo’s Wegovy Pill Crushes Lilly’s Foundayo in Early Weight-Loss Battle
Novo Nordisk’s Wegovy pill is dominating early sales with 8x more prescriptions than Eli Lilly’s Foundayo.